| scholarly article | Q13442814 |
| P50 | author | Balwinder Singh | Q37840944 |
| Stacey J Winham | Q56516227 | ||
| Susan L McElroy | Q56816544 | ||
| Marin Veldic | Q75191736 | ||
| Joanna M Biernacka | Q87669965 | ||
| Mark A Frye | Q90298035 | ||
| Brandon Coombes | Q93176250 | ||
| Francisco Romo-Nava | Q93233643 | ||
| Miguel L Prieto | Q95963196 | ||
| Alejandra Cabello Arreola | Q117263712 | ||
| P2093 | author name string | Katherine M Moore | |
| Simon Kung | |||
| Hannah K Betcher | |||
| Nicolas A Nunez | |||
| Alfredo B Cuéllar-Barboza | |||
| P2860 | cites work | Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis | Q22242068 |
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| Review of pharmacological treatment in mood disorders and future directions for drug development. | Q26853509 | ||
| Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics | Q28081249 | ||
| Evaluating historical candidate genes for schizophrenia | Q28082318 | ||
| GADL1 variant and medication adherence in predicting response to lithium maintenance treatment in bipolar I disorder | Q30490129 | ||
| Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol | Q30572528 | ||
| The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders | Q30583384 | ||
| Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data | Q30957546 | ||
| Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. | Q33782489 | ||
| The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study | Q33850634 | ||
| Historical perspectives and natural history of bipolar disorder | Q33920209 | ||
| Functional impairment and cognition in bipolar disorder | Q34057133 | ||
| Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles | Q34138234 | ||
| The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism | Q34330986 | ||
| GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis | Q34400329 | ||
| Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients | Q50082460 | ||
| The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients | Q34502691 | ||
| Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder | Q34540294 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 | ||
| Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort | Q34658720 | ||
| Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response | Q35040545 | ||
| Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis | Q35222401 | ||
| Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities | Q35634683 | ||
| Exploring the role of drug-metabolising enzymes in antidepressant side effects | Q35780023 | ||
| Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients | Q35837256 | ||
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors | Q35883249 | ||
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system | Q35995415 | ||
| Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis | Q36148530 | ||
| Role of glutamate decarboxylase-like protein 1 (GADL1) in taurine biosynthesis | Q36435992 | ||
| Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder | Q36546243 | ||
| Lithium response and genetic variation in the CREB family of genes | Q36548273 | ||
| Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder | Q36580824 | ||
| Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study | Q36746449 | ||
| Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors | Q37037058 | ||
| Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder | Q37199024 | ||
| Abandoning personalization to get to precision in the pharmacotherapy of depression | Q37274682 | ||
| Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations | Q37344782 | ||
| A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. | Q37536783 | ||
| Lithium response across generations | Q37609499 | ||
| Prediction of CYP2D6 phenotype from genotype across world populations | Q37625633 | ||
| Mania associated with antidepressant treatment: comprehensive meta-analytic review | Q37643765 | ||
| Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses | Q37793826 | ||
| The pharmacogenetics of antidepressant‐induced mania: a systematic review and meta‐analysis | Q37805730 | ||
| Clinical practice. Bipolar disorder--a focus on depression | Q37826189 | ||
| Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association | Q37890609 | ||
| GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder | Q37982704 | ||
| Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force | Q38081648 | ||
| Pharmacogenetics of antiepileptic drug-induced hypersensitivity | Q38217627 | ||
| HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis | Q38242739 | ||
| Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population. | Q50541774 | ||
| Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. | Q50656709 | ||
| Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. | Q51285380 | ||
| The utility of pharmacogenetic testing to support the treatment of bipolar disorder. | Q51733691 | ||
| Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. | Q51794510 | ||
| Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. | Q51899995 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. | Q52656684 | ||
| Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. | Q53595452 | ||
| AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. | Q54483615 | ||
| Prediction of response to drug therapy in psychiatric disorders. | Q55002697 | ||
| Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies | Q56353844 | ||
| No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample | Q56988477 | ||
| Modelling mood disorders: An ACE solution? | Q57455353 | ||
| Convergent analysis of genome-wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder | Q57466637 | ||
| Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis | Q57491589 | ||
| Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder and treatment response: A systematic review and meta-analysis | Q58492729 | ||
| Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective | Q58698797 | ||
| Evidence for association of anACCN1gene variant with response to lithium treatment in Sardinian patients with bipolar disorder | Q58875291 | ||
| GSK-3b 50 T/C polymorphism in bipolar disorder and its relationship with clinical phenotypes and treatment response | Q60417958 | ||
| Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications | Q64228579 | ||
| The voltage-gated sodium channel gene SCN2A and idiopathic generalized epilepsy | Q77336688 | ||
| Is response to prophylactic lithium a familial trait? | Q78475020 | ||
| Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole | Q81166817 | ||
| GADL1 gene polymorphisms and lithium response in bipolar I disorder: lack of association from an Indian population | Q86035842 | ||
| Preventing the Malignant Transformation of Bipolar Disorder | Q87972581 | ||
| Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study | Q88592186 | ||
| The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine | Q88780379 | ||
| Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools | Q88796940 | ||
| Opportunities and obstacles in genotypic prediction of cytochrome P450 phenotypes | Q88973397 | ||
| Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study | Q89995863 | ||
| PharmVar GeneFocus: CYP2D6 | Q90208070 | ||
| Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials | Q90299026 | ||
| Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? | Q90560186 | ||
| Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study | Q91200569 | ||
| Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration | Q91246921 | ||
| Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study | Q91398968 | ||
| Clinical applications of CYP genotyping in psychiatry. | Q38247063 | ||
| Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy | Q38645670 | ||
| Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder | Q38735900 | ||
| Commercial pharmacogenetic-based decision-support tools in psychiatry | Q38822416 | ||
| Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis | Q38842714 | ||
| Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine | Q38862332 | ||
| Lithium Pharmacogenetics: Where Do We Stand? | Q38955537 | ||
| ABCB1 genotyping in the treatment of depression | Q39029387 | ||
| Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania | Q39051772 | ||
| Pharmacogenomic aspects of bipolar disorder: An update | Q39200357 | ||
| Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression | Q39312381 | ||
| Patient preferences for pharmacogenetic screening in depression | Q39324637 | ||
| Genetics and pharmacogenetics of mood disorders | Q39350973 | ||
| Genomics of Lithium Action and Response | Q39390032 | ||
| Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. | Q39613623 | ||
| The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. | Q40769848 | ||
| Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics | Q40851029 | ||
| Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population | Q41541871 | ||
| D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis | Q42056580 | ||
| C825T Polymorphism of the GNB3 Gene on Valproate-Related Metabolic Abnormalities in Bipolar Disorder Patients | Q42918757 | ||
| Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder | Q43074580 | ||
| Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. | Q44730960 | ||
| Genetic differences in cytochrome P450 enzymes and antidepressant treatment response | Q45729383 | ||
| Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. | Q45947628 | ||
| Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update | Q46091944 | ||
| Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. | Q46177262 | ||
| Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder | Q46189290 | ||
| Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients | Q46238863 | ||
| Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression | Q46434348 | ||
| Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. | Q46686779 | ||
| Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder | Q46919165 | ||
| Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes | Q47389044 | ||
| Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. | Q47546923 | ||
| Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. | Q47553781 | ||
| The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder | Q47582171 | ||
| The Emerging Neurobiology of Bipolar Disorder | Q47698386 | ||
| Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population. | Q47808564 | ||
| Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population. | Q47825016 | ||
| Pharmacogenomics: Precision Medicine and Drug Response | Q47860317 | ||
| Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings? | Q47894175 | ||
| SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. | Q47998164 | ||
| A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate | Q48064476 | ||
| No evidence for GADL1 variation as a bipolar disorder susceptibility factor in a Caucasian lithium-responsive cohort | Q48141790 | ||
| Variant GADL1 and response to lithium therapy in bipolar I disorder | Q48381188 | ||
| Relevance of CYP2C9 Function in Valproate Therapy. | Q48606325 | ||
| P433 | issue | 1 | |
| P921 | main subject | bipolar disorder | Q131755 |
| decision support system | Q330268 | ||
| P304 | page(s) | 23 | |
| P577 | publication date | 2020-07-04 | |
| P1433 | published in | International journal of bipolar disorders | Q27725397 |
| P1476 | title | Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection | |
| P478 | volume | 8 |
Search more.